Selectivity of Docking Sites in MAPK Kinases*

Protein kinases often recognize their substrates and regulators through docking interactions that occur outside of the active site; these interactions can help us to understand kinase networks, and to target kinases with drugs. During mitogen-activated protein kinase (MAPK) signaling, the ability of MAPK kinases (MKKs, or MEKs) to recognize their cognate MAPKs is facilitated by a short docking motif (the D-site) in the MKK N terminus, which binds to a complementary region on the MAPK. MAPKs then recognize many of their targets using the same strategy, because many MAPK substrates also contain D-sites. The extent to which docking contributes to the specificity of MAPK transactions is incompletely understood. Here we characterize the selectivity of the interaction between MKK-derived D-sites and MAPKs by measuring the ability of D-site peptides to inhibit MAPK-mediated phosphorylation of D-site-containing substrates. We find that all MKK D-sites bind better to their cognate MAPKs than they do to non-cognate MAPKs. For instance, the MKK3 D-site peptide, which is a remarkably potent inhibitor of p38α (IC50 < 10 nm), does not inhibit JNK1 or JNK2. Likewise, MAPKs generally bind as well or better to cognate D-sites than to non-cognate D-sites. For instance, JNK1 and JNK2 do not appreciably bind to any D-sites other than their cognate D-sites from MKK4 and MKK7. In general, cognate, within-pathway interactions are preferred about an order of magnitude over non-cognate interactions. However, the selectivity of MAPKs and their cognate MKK-derived D-sites for each other is limited in some cases; in particular, ERK2 is not very selective. We conclude that MAPK-docking sites in MAPK kinases bind selectively to their cognate MAPKs.

[1]  K. Parang,et al.  Design strategies for protein kinase inhibitors. , 2004, Current opinion in drug discovery & development.

[2]  Lee Bardwell,et al.  Docking sites on mitogen-activated protein kinase (MAPK) kinases, MAPK phosphatases and the Elk-1 transcription factor compete for MAPK binding and are crucial for enzymic activity. , 2003, The Biochemical journal.

[3]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[4]  Jiahuai Han,et al.  Structure-Function Studies of p38 Mitogen-activated Protein Kinase , 1997, The Journal of Biological Chemistry.

[5]  Radha Akella,et al.  Unique MAP Kinase binding sites. , 2008, Biochimica et biophysica acta.

[6]  Lance R. Martin,et al.  The anti-apoptotic protein PEA-15 is a tight binding inhibitor of ERK1 and ERK2, which blocks docking interactions at the D-recruitment site. , 2007, Biochemistry.

[7]  Frank McCormick,et al.  Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. , 2007, Human molecular genetics.

[8]  L. Bardwell,et al.  A conserved motif at the amino termini of MEKs might mediate high-affinity interaction with the cognate MAPKs. , 1996, Trends in biochemical sciences.

[9]  D. Swinney,et al.  Kinetic characterization of human JNK2alpha2 reaction mechanism using substrate competitive inhibitors. , 2007, Biochemistry.

[10]  T. Herdegen,et al.  Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. , 2005, Trends in pharmacological sciences.

[11]  Kazuhiro Nakamura,et al.  The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. , 2007, Biochimica et biophysica acta.

[12]  L. Bardwell,et al.  Characterization of an ERK-binding Domain in Microphthalmia-associated Transcription Factor and Differential Inhibition of ERK2-mediated Substrate Phosphorylation* , 2005, Journal of Biological Chemistry.

[13]  P. Lograsso,et al.  Kinetic mechanism and inhibitor characterization for c-jun-N-terminal kinase 3alpha1. , 2008, Biochemistry.

[14]  Lee Bardwell,et al.  A conserved protein interaction network involving the yeast MAP kinases Fus3 and Kss1 , 2004, The Journal of cell biology.

[15]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[16]  Chunli Shao,et al.  The roles of MAPKs in disease , 2008, Cell Research.

[17]  E. Goldsmith,et al.  Phosphorylation of MAP Kinases by MAP/ERK Involves Multiple Regions of MAP Kinases* , 1999, The Journal of Biological Chemistry.

[18]  W. Lim,et al.  Domains, motifs, and scaffolds: the role of modular interactions in the evolution and wiring of cell signaling circuits. , 2006, Annual review of biochemistry.

[19]  B. Cairns,et al.  Signaling in the yeast pheromone response pathway: specific and high-affinity interaction of the mitogen-activated protein (MAP) kinases Kss1 and Fus3 with the upstream MAP kinase kinase Ste7 , 1996, Molecular and cellular biology.

[20]  Wendell A Lim,et al.  The role of docking interactions in mediating signaling input, output, and discrimination in the yeast MAPK network. , 2005, Molecular cell.

[21]  H. Enslen,et al.  Molecular determinants that mediate selective activation of p38 MAP kinase isoforms , 2000, The EMBO journal.

[22]  Masahiko Hibi,et al.  c-Jun Can Recruit JNK to Phosphorylate Dimerization Partners via Specific Docking Interactions , 1996, Cell.

[23]  J. Boehm,et al.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases , 2003, Nature Reviews Drug Discovery.

[24]  Bo Zhou,et al.  Structural basis of docking interactions between ERK2 and MAP kinase phosphatase 3. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[25]  W. Lim,et al.  Docking interactions in protein kinase and phosphatase networks. , 2006, Current opinion in structural biology.

[26]  Lee Bardwell,et al.  A Docking Site in MKK4 Mediates High Affinity Binding to JNK MAPKs and Competes with Similar Docking Sites in JNK Substrates* , 2003, Journal of Biological Chemistry.

[27]  Tony Pawson,et al.  Specificity in Signal Transduction From Phosphotyrosine-SH2 Domain Interactions to Complex Cellular Systems , 2004, Cell.

[28]  Jason A. Papin,et al.  Reconstruction of cellular signalling networks and analysis of their properties , 2005, Nature Reviews Molecular Cell Biology.

[29]  E. Nishida,et al.  A conserved docking motif in MAP kinases common to substrates, activators and regulators , 2000, Nature Cell Biology.

[30]  Radha Akella,et al.  Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b. , 2002, Molecular cell.

[31]  A. Cuenda,et al.  p38 MAP-kinases pathway regulation, function and role in human diseases. , 2007, Biochimica et biophysica acta.

[32]  Bostjan Kobe,et al.  Uses for JNK: the Many and Varied Substrates of the c-Jun N-Terminal Kinases , 2006, Microbiology and Molecular Biology Reviews.

[33]  Paul Shapiro,et al.  Mitogen activated protein (MAP) kinases: development of ATP and non-ATP dependent inhibitors. , 2006, Medicinal chemistry (Shariqah (United Arab Emirates)).

[34]  J. Wilsbacher,et al.  The N-terminal ERK-binding Site of MEK1 Is Required for Efficient Feedback Phosphorylation by ERK2 in Vitro and ERK Activation in Vivo * , 1999, The Journal of Biological Chemistry.

[35]  N. Ahn,et al.  Signal transduction through MAP kinase cascades. , 1998, Advances in cancer research.

[36]  Keisuke Kuida,et al.  Inhibitors of Protein Kinase Signaling Pathways: Emerging Therapies for Cardiovascular Disease , 2004, Circulation.

[37]  Jiahuai Han,et al.  Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms , 1995, Science.

[38]  Sam-Yong Park,et al.  Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125 , 2004, The EMBO journal.

[39]  L. Bardwell,et al.  Mitogen-activated protein kinase (MAPK)-docking sites in MAPK kinases function as tethers that are crucial for MAPK regulation in vivo. , 2006, Cellular signalling.

[40]  Nobuyuki Tanaka,et al.  Mechanism of p38 MAP kinase activation in vivo. , 2003, Genes & development.

[41]  Nils Blüthgen,et al.  Competing docking interactions can bring about bistability in the MAPK cascade. , 2007, Biophysical journal.

[42]  A. Turjanski,et al.  MAP kinases and the control of nuclear events , 2007, Oncogene.

[43]  M. Karin,et al.  Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. , 1995, Science.

[44]  Brian K. Wilson,et al.  Proximity-induced catalysis by the protein kinase ERK2. , 2005, Journal of the American Chemical Society.

[45]  B. Turk.  Manipulation of host signalling pathways by anthrax toxins. , 2007, The Biochemical journal.

[46]  A. Sharrocks,et al.  Docking domains and substrate-specificity determination for MAP kinases. , 2000, Trends in biochemical sciences.

[47]  C. Tournier,et al.  A Novel Mitogen-Activated Protein Kinase Docking Site in the N Terminus of MEK5α Organizes the Components of the Extracellular Signal-Regulated Kinase 5 Signaling Pathway , 2005, Molecular and Cellular Biology.

[48]  A. Brunet,et al.  Identification of MAP Kinase Domains by Redirecting Stress Signals into Growth Factor Responses , 1996, Science.

[49]  Protein kinases and their therapeutic exploitation. , 2007, Biochemical Society transactions.

[50]  E. Goldsmith,et al.  Contributions of the Mitogen-activated Protein (MAP) Kinase Backbone and Phosphorylation Loop to MEK Specificity* , 1996, The Journal of Biological Chemistry.

[51]  H. Eldar-Finkelman,et al.  Peptides targeting protein kinases: strategies and implications. , 2006, Physiology.

[52]  L. Bardwell,et al.  Mechanisms of MAPK signalling specificity. , 2006, Biochemical Society transactions.

[53]  A. Sharrocks,et al.  The Elk-1 ETS-Domain Transcription Factor Contains a Mitogen-Activated Protein Kinase Targeting Motif , 1998, Molecular and Cellular Biology.

[54]  Radha Akella,et al.  Substrate and docking interactions in serine/threonine protein kinases. , 2007, Chemical reviews.

[55]  C. Tournier,et al.  Physiological roles of MKK4 and MKK7: insights from animal models. , 2006, Biochimica et biophysica acta.

[56]  L. Flatauer,et al.  A Conserved Docking Site in MEKs Mediates High-affinity Binding to MAP Kinases and Cooperates with a Scaffold Protein to Enhance Signal Transmission* , 2001, The Journal of Biological Chemistry.

[57]  R. Davis,et al.  Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[58]  A. Vercelli,et al.  A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia , 2003, Nature Medicine.

[59]  Marc W. Kirschner,et al.  How Proteolysis Drives the Cell Cycle , 1996, Science.

[60]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[61]  C. Murga,et al.  Interfering with MAP Kinase Docking Interactions: Implications and Perspectives for the p38 Route , 2007, Cell cycle.

[62]  Jiahuai Han,et al.  Characterization of the Structure and Function of a Novel MAP Kinase Kinase (MKK6) (*) , 1996, The Journal of Biological Chemistry.

[63]  Lee Bardwell,et al.  Interacting JNK-docking Sites in MKK7 Promote Binding and Activation of JNK Mitogen-activated Protein Kinases* , 2006, Journal of Biological Chemistry.

[64]  A. Bardwell,et al.  Anthrax lethal factor-cleavage products of MAPK (mitogen-activated protein kinase) kinases exhibit reduced binding to their cognate MAPKs. , 2004, The Biochemical journal.

[65]  M. Cobb,et al.  Identification of Novel Point Mutations in ERK2 That Selectively Disrupt Binding to MEK1* , 2002, The Journal of Biological Chemistry.

[66]  R. Seger,et al.  The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions , 2006, Growth factors.

[67]  M. Karin,et al.  Molecular cloning and characterization of human JNKK2, a novel Jun NH2-terminal kinase-specific kinase , 1997, Molecular and cellular biology.

[68]  D. Fairlie,et al.  A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. , 2007, Drug discovery today.

[69]  R. Davis,et al.  Regulation of MAP kinases by docking domains , 2001, Biology of the cell.

[70]  Andrew F Neuwald,et al.  The hallmark of AGC kinase functional divergence is its C-terminal tail, a cis-acting regulatory module , 2007, Proceedings of the National Academy of Sciences.